Mind Medicine (MindMed) Inc
MNMD15.020USD
0.0000.00%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
1.15BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Mind Medicine (MindMed) Inc Unternehmen
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Mind Medicine (MindMed) Inc Informationen
BörsenkürzelMNMD
Name des UnternehmensMind Medicine (MindMed) Inc
IPO-datumMay 04, 2015
CEOBarrow (Robert B)
Anzahl der mitarbeiter74
WertpapierartOrdinary Share
GeschäftsjahresendeMay 04
AddresseOne World Trade Center
StadtNEW YORK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10007
Telefon12122206633
Websitehttps://ir.mindmed.co/
BörsenkürzelMNMD
IPO-datumMay 04, 2015
CEOBarrow (Robert B)
Führungskräfte von Mind Medicine (MindMed) Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
198.46K
-25791.00%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
20.08K
-11276.00%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+5402.00%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+5402.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-9234.00%
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Chris Brinzey
Mr. Chris Brinzey
IR Contact Officer
IR Contact Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
198.46K
-25791.00%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
20.08K
-11276.00%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+5402.00%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+5402.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-9234.00%
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: 2 hours ago
Aktualisiert: 2 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
5.34%
Commodore Capital LP
3.27%
Driehaus Capital Management, LLC
3.16%
Blackstone Alternative Asset Management, L.P.
2.82%
The Vanguard Group, Inc.
2.61%
Andere
82.80%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
5.34%
Commodore Capital LP
3.27%
Driehaus Capital Management, LLC
3.16%
Blackstone Alternative Asset Management, L.P.
2.82%
The Vanguard Group, Inc.
2.61%
Andere
82.80%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
16.80%
Investment Advisor
13.42%
Hedge Fund
11.26%
Research Firm
1.58%
Individual Investor
1.28%
Private Equity
0.37%
Bank and Trust
0.33%
Pension Fund
0.13%
Venture Capital
0.10%
Andere
54.72%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
415
43.34M
43.99%
-6.62M
2025Q3
385
42.65M
43.29%
-5.82M
2025Q2
380
42.59M
55.97%
-6.05M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
5.26M
5.34%
+38.15K
+0.73%
Sep 30, 2025
Commodore Capital LP
3.23M
3.27%
-1.77M
-35.50%
Sep 30, 2025
Driehaus Capital Management, LLC
3.11M
3.16%
+17.25K
+0.56%
Sep 30, 2025
Blackstone Alternative Asset Management, L.P.
2.78M
2.82%
-810.92K
-22.60%
Sep 30, 2025
The Vanguard Group, Inc.
2.00M
2.03%
+198.88K
+11.04%
Sep 30, 2025
Marshall Wace LLP
2.38M
2.42%
-1.04M
-30.38%
Sep 30, 2025
Octagon Capital Advisors LP
2.13M
2.16%
--
--
Sep 30, 2025
State Street Investment Management (US)
1.92M
1.95%
+119.00K
+6.59%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.82M
1.85%
+91.25K
+5.26%
Sep 30, 2025
Deep Track Capital LP
1.50M
1.52%
-1.00M
-40.00%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
AdvisorShares Psychedelics ETF
9.95%
State Street SPDR S&P Pharmaceuticals ETF
2.17%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.54%
Virtus LifeSci Biotech Clinical Trials ETF
1.32%
iShares U.S. Pharmaceuticals ETF
0.4%
iShares Micro-Cap ETF
0.21%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
Nuveen ESG Small-Cap ETF
0.08%
iShares ESG Aware MSCI USA Small-Cap ETF
0.07%
Mehr Anzeigen
AdvisorShares Psychedelics ETF
Anteil9.95%
State Street SPDR S&P Pharmaceuticals ETF
Anteil2.17%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.54%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.32%
iShares U.S. Pharmaceuticals ETF
Anteil0.4%
iShares Micro-Cap ETF
Anteil0.21%
ProShares Ultra Nasdaq Biotechnology
Anteil0.11%
Invesco Nasdaq Biotechnology ETF
Anteil0.11%
Nuveen ESG Small-Cap ETF
Anteil0.08%
iShares ESG Aware MSCI USA Small-Cap ETF
Anteil0.07%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
